anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cosmetic cleaning compositions comprising a) at least one surfactant selected from anionic, amphoteric, zwitterionic and/or nonionic surfactants, b) at least one naturally occurring gel former and c) particles containing at least two constituents from at least two different groups i. to viii.: i. optionally aftertreated pyrogenic silica, ii. microcrystalline cellulose and/or cellulose ether, iii. polyols having 3 to 8 carbon atoms, iv. dyes, v. vitamins, vi. oils and/or waxes, vii. plant extracts in powder form, viii. charcoal, are suitable for use as cosmetic hair cleaning products for improving a very wide variety of haircare parameters, and in particular for increasing hair volume, improving hair hand, reducing weighing-down of hair and/or reducing frizz.
Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
The embodiment of the application provides a vehicle leaving interaction method and device based on nucleic acid detection and electronic equipment, and relates to the technical field of network appointment vehicles. And judging whether the service provider has a nucleic acid detection identifier or not by responding to a departure request initiated by the service provider at a departure interactive interface. And if the service provider is determined not to have the nucleic acid detection identifier, displaying a nucleic acid detection uploading interface. And responding to an uploading request of the service provider on the nucleic acid detection uploading interface to obtain the nucleic acid detection information. And sending the nucleic acid detection information to the server, and receiving the identification result information returned by the server based on the nucleic acid detection information. The service provider is configured with the nucleic acid detection identifier or the service suspension identifier based on the identifier result information, so that the supervision difficulty of supervising the service provider to take protective measures is reduced, the phenomenon that the infection source exists in the network appointment journey to cause people transmission is fundamentally avoided, and the safety of taking the network appointment for travel by a user is improved.
This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
Neuronal ceroid lipofuscinoses (NCLs), commonly known as Batten disease, represent a group of the most common (1 in 12,500) heritable neurodegenerative storage disorders of childhood. Mutations of at least 8 different genes are responsible for various forms of NCL. The infantile form of NCL or INCL is the most severe disease. It is caused by mutations in the palmitoyl-protein thioesterase-1 (PPT1) gene. PPT1 is a lysosomal enzyme that cleaves thioester linkages in S-acylated proteins and its deficiency leads to abnormal lysosomal accumulation of fattyacylated- proteins (ceroids) leading to INCL pathogenesis. Since thioester linkages are labile, drugs with nucleophilic property are likely to mimic PPT1 and may have therapeutic potential for INCL. We previously reported that cysteamine, phosphocysteamine, cysteamine bitartrate (cystagon) and N-acetylcysteine disrupt thioester linkages in a model PPT1-substrate, C(14) palmitoyl-CoA, releasing C(14) palmitic acid. The results of our laboratory studies have shown that cysteamine mediates the depletion of intracellular ceroid deposits and prevents their reaccumulation. For the last 9 years, we have been conducting a clinical trial to determine whether a combination of Cystagon (Cysteamine bitartrate) and N-acetylcysteine (mucomyst) is beneficial for INCL patients. In parallel with these studies, using an animal model of INCL we found that this combination therapy reduces oxidative stress caused by high levels of reactive oxygen species (ROS) in the brain of mice lacking the PPT1 enzyme. To date, we have admitted a total of 10 patients (5 females and 5 males) to this protocol; however, one male patient was lost to follow-up. Thus, we have treated 9 patients (5 females and 4 males) and these patients showed no adverse reactions to these drugs except for one patient who initially had mild gastrointestinal discomfort which went away when cystagon was stopped and restarted from the lowest dose and this mild adverse effect did not recur. Compared with the published natural history of INCL, our preliminary results show that although several parameters of disease progression are slowed due to the treatment it does not completely arrest the neurodegenerative process. We are currently analyzing all the data gathered so far and a manuscript describing the results will be prepared for submission to a peer-reviewed journal.
The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA.  Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine. The invention also includes a method for diagnosing cancer and monitoring its progression. This aspect of the invention involves isolating serum from a patient; measuring the concentration of endo-exonuclease in said serum and determining whether said concentration is above a predetermined mean.
PROBLEM TO BE SOLVED: To provide a medical image control system and a portable terminal for supporting a medical activity by the portable terminal.SOLUTION: A medical image control system of an embodiment comprises a medical image diagnosis device and a portable terminal. The medical image diagnosis device includes a collection unit, a distribution unit and a reflection unit. The collection unit takes moving pictures of an object following predetermined photographic conditions to collect moving picture data. The distribution unit spontaneously distributes the moving picture data to the portable terminal. The reflection unit receives control information transmitted from the portable terminal, and reflects the received control information on processing by the medical image diagnosis device. The portable terminal includes a reproduction unit and a control information transmission unit. The reproduction unit receives the moving picture data distributed by the distribution unit, and spontaneously reproduces the received moving picture data. The control information transmission unit accepts operation relating to the medical image diagnosis device, and transmits the control information showing the accepted operation content to the medial image diagnosis device.
PCT No. PCT/SE81/00065 Sec. 371 Date Nov. 2, 1981 Sec. 102(e) Date Nov. 2, 1981 PCT Filed Mar. 5, 1981 PCT Pub. No. WO81/02520 PCT Pub. Date Sep. 17, 1981.Compositions and methods useful for identification or diagnostic use, or inhibition of adherence of uropathogenic bacteria to cells, all in connection with uropathogenic bacterial infections, containing as an active constituent the structural element, preferably in terminal position:  alpha -D-Galp-(1-4)-D-Gal. A process for identification or quantification of such structural element in native biological material from mammals including man, comprising using antibodies, the generation of which has been initiated by such composition. A process for the identification of bacterial acceptor structures (pili, syn. fimbriae) recognizing the described structural element, comprising using this recognition. A process for purifying acceptor structures of bacteria, comprising using for the purification the affinity between such structural element and the corresponding acceptor structures on the bacteria. A method of diagnosing mammals including man in regard to a tendency toward bacterial infection involving such receptor structure, comprising generating antibodies against said receptor structure and recording the reaction of said antibodies and cells from the mammal.
The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
Menstrual pain is known to be caused by increased tension in the uterine muscles and irregular contractions, and is experienced by 50% of women who menstruate. However, most people control pain with NSAIDs or hormones. Among non-pharmacological treatments, manual therapy is known to control menstrual pain by influencing pain perception and pain-related serological factors. Previous research results have shown that manual therapy using sacroiliac joint correction and high-speed, low-amplitude thrust techniques is effective for menstrual pain. However, there is still no randomized controlled study limited to Chuna therapy. Therefore, the investigators would like to conduct a randomized clinical study to determine the effectiveness and safety of Chuna therapy for primary dysmenorrhea.
Low viscosity silicone compsns. which have been rendered hydrophilic are used in conjunction with addn. crosslinking hardeners for taking dental impressions which are used in making moulds for dental prostheses. USE/ADVANTAGE - The silicone compsns. give impressions of higher accuracy than the high water content gel a conventionally used, and show virtually no after-shrinkage so that the dimensions are accurately reproduced. The hydrophilic surface of the impression allows water-contg. modelling materials introduced into the impression to penetrate into the finest crevises of the impression so that a model of very high precision is produced from which prostheses of very high accuracy can be produced.
Patients will start metformin at 1,000mg by mouth once daily during a 7-day induction period prior to starting zimberelimab. The dose will be increased by 500mg every 7 days until reaching the target dose of 2000mg. Zimberelimab will be administered at a fixed dose of 240 mg IV every 14 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity, or withdrawal of consent.
The research will be carried out with young girls who are studying at the Faculty of Health Sciences of Sinop University in the 2022-2023 academic spring semester. Inclusion criteria for the research: Faculty of Health Sciences, to study in the 2022-2023 academic spring semester, to have been diagnosed with migraine, to be young girls and to volunteer to participate in the research. Exclusion criteria from the study; Not studying at the Faculty of Health Sciences and not volunteering to participate in the research. The application and control group will be determined on random.org among the group that constitutes the sample of the study. Laughter therapy sessions will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. At the end of two months, the Personal Information Form and Psychological Well-Being Scale will be administered again to both the application group and the control group.
Prostanoids are inflammatory mediators that have been implicated in all stages of acute and chronic inflammation. The inhibition of prostanoid synthesis by NSAIDs forms the basis of their therapeutic as well as side effects. NSAIDs directly inhibit cyclooxygenase \[COX\], which leads to reduction of prostaglandin synthesis but also to gastric erosions, inhibition of platelet aggregation and nephrotoxicity. The identification of the two isoforms of COX lead to the hypothesis that COX-2 is responsible for the production of prostaglandins following tissue injury, while COX-1 is involved in normal homeostasis. This hypothesis is primarily based on the results of animal studies and chronic inflammatory conditions such as arthritis. Recent results in the oral surgery model of acute inflammation suggest that COX-2 is present in the oral mucosa and may contribute to prostanoid production during acute inflammation rather than require induction in response to the injury. The proposed study aims to evaluate the time course of COX-1 and COX-2 in acute inflammation by evaluating levels of mRNA at baseline prior to surgery, at the completion of surgery, and at one, two and three hours following surgery.
PURPOSE:To obtain an antitumor agent useful especially for treating and preventing tumor of digestive organ, having excellently inhibitory action on formation of tumor and extremely low toxicity, comprising metallothionein as an active ingredient. CONSTITUTION:An antitumor agent containing a metallothionein, a substance wherein protein and a metal ion are linked by chelate bond, preferably zinc metallothionein as an active ingredient. Metallothionein is obtained by homoge nizing a mammalian liver with about 0.1-0.5M sucrose, centrifuging at 10,000-30,000G for 10-60min, then at 50,000-200,000G for 1-2hr to recover a soluble cytoplasmic fraction, then subjecting to gel filtration using a gel filtration carrier having about 1,000-100,000mol.wt. range to be fractioned, recovering an active fraction (fraction corresponding to about 5,000-10,000mol.wt.) and carrying out chromatography using an anion exchanger. A dose of the active ingredient is preferably 1-5mg per adult daily.
PURPOSE:The titled complex useful remedying hemorrhage of a patient of hemophilia, having raised preservation stability of the factor VIII and purification degree, obtained by bringing phospholipid into contact with blood coagulation factor. CONSTITUTION:For example, phospholipid (e.g., phosphatidylcholine, or phosphatidic acid) is dissoved in a solvent (e.g., CHCl3, ethanol, etc.), the solvent is distilled away, so that a thin film of phospholipid is formed in the inner face of a container. The formed film is shaked, stirred, and destroyed to prepare particles. The particles are preferably treated with ultrasonic wave, and adjusted to <=0.3mu particle diameters. The particles are blended and brought into contact with blood coagulation factor VIII, to give a complex of blood coagulation factor VIIIand phospholipid. The complex has 2-25 times as much activity as that of the factor VIII, and 88-96wt% recovery ratio. It has also high preservation stability. Intravenous injection is made possible by adjusting the complex to proper particle diameter.
Recombinant interleukin-22 (rIL-22) has been reported as a protective agent in murine models of diseases driven by epithelial injury. Parasites have a circadian rhythm and their sensitivity to a certain drug may vary during the day. Therefore, this work aimed to investigate the effect of rIL-22 administration at different times of the day on the inflammation, oxidative status, and neurotransmitter release in the gut-brain axis of the Schistosoma mansoni-infected mice. Sixty male BALB/c mice aged six weeks weighing 25-30 g were divided into a control group (injected intraperitoneally with PBS), mice infected with 80 ± 10 cercariae of S. mansoni (infected group) then injected intraperitoneally with PBS, and rIL-22 treated groups. rIL-22 was administrated intraperitoneally (400 ng/kg) either at the onset or offset of the light phase for 14 days. IL-22 administration reduced the levels of IL-1β, tumor necrosis factor-alpha (TNF-α), nuclear factor kappa beta (NF-κβ), and enhanced the production of IL-22 and IL-17. The treatment with IL-22 increased glutathione (GSH) and reduced malondialdehyde (MDA) and nitric oxide (NO) levels both in the ileum and brain. The B-cell lymphoma 2 (BCL2) protein level in the ileum was diminished after IL-22 administration. Brain-derived neurotrophic factor (BDNF) and neurotransmitter release (serotonin, 5HT, norepinephrine, NE, dopamine, DA, Glutamate, Glu, and -amino butyric acid, GABA) were improved by rIL-22. In conclusion, rIL-22 showed promising immunotherapy for inflammation, oxidative damage, and neuropathological signs associated with schistosomiasis. The efficacy of IL-22 increased significantly upon its administration at the time of light offset.
Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
For patients preferring a brief course of stabilization followed by a period of medically supervised withdrawal, it is generally recommended that the patient be titrated to a total daily dose of about 40 mg in divided doses to achieve an adequate stabilizing level. Stabilization can be continued for 2 to 3 days, after which the dose of methadone should be gradually decreased. The rate at which methadone is decreased should be determined separately for each patient. 

The dose of methadone can be decreased on a daily basis or at 2-day intervals, but the amount of intake should remain sufficient to keep withdrawal symptoms at a tolerable level. In hospitalized patients, a daily reduction of 20% of the total daily dose may be tolerated. In ambulatory patients, a somewhat slower schedule may be needed.
The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a "slushy" consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer.
Morphological and structural remodeling of the heart, including cardiac hypertrophy and fibrosis, has been considered as a therapeutic target for heart failure for approximately three decades. Groundbreaking heart failure medications demonstrating reverse remodeling effects have contributed significantly to medical advancements. However, nearly 50% of heart failure patients still exhibit drug resistance, posing a challenge to the healthcare system. Recently, characteristics of heart failure resistant to ARBs and β-blockers have been defined, highlighting preserved systolic function despite impaired diastolic function, leading to the classification of heart failure with preserved ejection fraction (HFpEF). The pathogenesis and aetiology of HFpEF may be related to metabolic abnormalities, as evidenced by its mimicry through endothelial dysfunction and excessive intake of high-fat diets. Our recent findings indicate a significant involvement of mitochondrial hyper-fission in the progression of heart failure. This mitochondrial pathological remodeling is associated with redox imbalance, especially hydrogen sulphide accumulation due to abnormal electron leak in myocardium. In this review, we also introduce a novel therapeutic strategy for heart failure from the current perspective of mitochondrial redox-metabolic remodeling.
Patients receive placebo instilled into the IPC which is capped for 1-2 hours before the catheter is drained. Beginning 1 week later, patients may receive alteplase as in arm I.
BACKGROUND: Indomethacin is administered as a tocolytic agent for threatening preterm labor <28weeks of gestation. Only a few, not conclusive, studies have investigated its nephrotoxicity in very low birth weight (VLBW) infants. We investigated whether indomethacin increases the incidence of acute kidney injury (AKI) among VLBW infants.
METHODS: This is a retrospective study including all VLBW infants born at our center between January 1, 2005, and December 31, 2013. Indomethacin was administered to women with preterm labor and intact membranes. Neonatal AKI was defined according to KDIGO classification. Univariate analyses were performed comparing VLBW infants exposed to and not exposed to indomethacin. In the multivariable model, the association of indomethacin and AKI was adjusted for patent ductus arteriosus, use of nephrotoxic medications, birth weight, and gestational age.
RESULTS: Five hundred seventy-five VLBW infants were included, 49 (8.5%) of whom were exposed to indomethacin in utero. The univariate analysis showed that infants exposed to indomethacin had lower birth weight, lower gestational age, and higher incidence of AKI than infants not exposed. The multivariable model adjusted for confounding factors confirmed an increased risk of AKI in relation to gestational age at birth <27 weeks, but not to indomethacin.
CONCLUSIONS: Our data suggest that extreme prematurity, but not the use of indomethacin, is associated with AKI.
MOTIVATION: Metastasis formation is a hallmark of cancer lethality. Yet, metastases are generally unobservable during their early stages of dissemination and spread to distant organs. Genomic datasets of matched primary tumors and metastases may offer insights into the underpinnings and the dynamics of metastasis formation.
RESULTS: We present metMHN, a cancer progression model designed to deduce the joint progression of primary tumors and metastases using cross-sectional cancer genomics data. The model elucidates the statistical dependencies among genomic events, the formation of metastasis, and the clinical emergence of both primary tumors and their metastatic counterparts. metMHN enables the chronological reconstruction of mutational sequences and facilitates estimation of the timing of metastatic seeding. In a study of nearly 5000 lung adenocarcinomas, metMHN pinpointed TP53 and EGFR as mediators of metastasis formation. Furthermore, the study revealed that post-seeding adaptation is predominantly influenced by frequent copy number alterations.
AVAILABILITY AND IMPLEMENTATION: All datasets and code are available on GitHub at https://github.com/cbg-ethz/metMHN.